Verification evidence is still being completed.
PDF / print export
Ascelia Pharma
Malmo, Sweden
- Verified lead
- Magnus Corfitzen
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Orphan Oncology, Drug Development, Imaging Agents, Oral Oncology, and Clinical Development
- Review cycle
- May 2026
- Full address
- Hyllie Boulevard 34, 215 32 Malmo, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Ascelia Pharma contact page confirming the Malmo headquarters address.
- Editorial note
- Ascelia Pharma is published because official company materials confirm current leadership, Malmo headquarters address, and a real orphan-oncology therapeutics platform.
Orphan Oncology, Drug Development, Imaging Agents, Oral Oncology, and Clinical Development
Official leadership disclosure, Official Malmo address disclosure, Clinical-stage oncology platform claim
Ascelia Pharma is published because official company materials confirm current leadership, Malmo headquarters address, and a real orphan-oncology therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Malmo, Sweden
Ascelia Pharma
Orphan Oncology, Drug Development, Imaging Agents, Oral Oncology, and Clinical Development · Clinical-stage therapeutics platform
Ascelia Pharma runs orphan oncology development, clinical program management, and drug candidate portfolio development in Malmo, Sweden.
- Lead
- Magnus Corfitzen (verified ↗)
- Address
- Hyllie Boulevard 34, 215 32 Malmo, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Orphan Oncology Development · Clinical Program Management · Drug Candidate Portfolio Development
- Founded
- 2013
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Magnus Corfitzen
CEO
Full addressHyllie Boulevard 34, 215 32 Malmo, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Ascelia Pharma contact page listing the Malmo headquarters address.
Open sourceClinical-stage therapeutics platform
Malmo, Sweden. Orphan Oncology, Drug Development, Imaging Agents, Oral Oncology, and Clinical Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Malmo address disclosure, Clinical-stage oncology platform claim
Orphan Oncology, Drug Development, Imaging Agents, Oral Oncology, and Clinical Development
Ascelia Pharma is published because official company materials confirm current leadership, Malmo headquarters address, and a real orphan-oncology therapeutics platform.
Editorial note
Ascelia Pharma is published because official company materials confirm current leadership, Malmo headquarters address, and a real orphan-oncology therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Orphan Oncology Development
Clinical Program Management
Drug Candidate Portfolio Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Oncology portfolio systems
Regulatory and corporate infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Ascelia Pharma located?
- Ascelia Pharma operates from Hyllie Boulevard 34, 215 32 Malmo, Sweden, Malmo, Sweden.
- Who runs Ascelia Pharma?
- Ascelia Pharma is led by Magnus Corfitzen, CEO. Verified 21 Mar 2026.
- What does Ascelia Pharma do?
- Ascelia Pharma runs orphan oncology development, clinical program management, and drug candidate portfolio development in Malmo, Sweden. Core capabilities: Orphan Oncology Development, Clinical Program Management, Drug Candidate Portfolio Development.
Editorial context
Related technical briefs
Briefs that name Malmo as a covered market or city.